Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- RaQualia, Eli Lilly of US Cease Research Collaboration for Analgesics
July 1, 2014
- Takeda CEO Defends Millennium, Nycomed Acquisitions as “Not Failures”
June 30, 2014
- Takeda CEO Counters Opposing Shareholders, Says Mr Weber Most Appropriate to Lead Drug Maker
June 30, 2014
- Astellas, UCB Japan File for Cimzia for Treatment-Naïve RA Patients
June 30, 2014
- Weber Becomes 1st Non-Japanese President of Takeda
June 27, 2014
- Eisai Files World’s 1st NDA for Anticancer Agent Lenvatinib in Japan
June 27, 2014
- BMKK to Begin Third-Party Investigation into Company Involvement in Sprycel Trial
June 26, 2014
- Kyowa Pres. Eyes Excursion into Authorized Generic Territory
June 26, 2014
- X-Linked Hypophosphatemia Treatment Improves Phosphate Metabolism in PI/II Study: Kyowa Kirin
June 26, 2014
- BI Japan Halts Development of Faldaprevir, Calls off Entry into Hepatitis C Field
June 26, 2014
- Nihon Chouzai Reaches Price Settlements with All Wholesalers; Expects to Avoid Reductions in Basic Dispensing Fees
June 25, 2014
- SGLT-2 Inhibitors Vigorously Increase in Anterio’s “Mind Share” Ranking in May
June 25, 2014
- Sanofi-Brand Generics of Diovan, Zometa Hit Shelves in Japan
June 24, 2014
- Diovan, Zometa Authorized Generics Now Available in Japan
June 24, 2014
- Plavix Grabs Top Spot in FY2013 Domestic Ethical Drug Sales Ranking
June 24, 2014
- Prevenar 13 Approved for Use in Elderly: Pfizer Japan
June 24, 2014
- Probe Finds Takeda’s Systematic Involvement in CASE-J Study, No Data Tampering
June 23, 2014
- Blopress AGs Scheduled for Release in Mid-September: ASKA
June 20, 2014
- Kyowa Kirin Starts PI Study of Aβ Peptide Antibody for Alzheimer's Disease in Europe
June 20, 2014
- Takeda Ceases Development of TAK-700 for Prostate Cancer on Lackluster PIII Results
June 20, 2014
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…